Dyspepsia due to Helicobacterpylori. Functional dyspepsia
Conditions
Interventions
Intervention 1: The intervention group includes people 18 years old and older who receive pills of Vitamin D with a dose of 50000 for 3 months.This drug should be taken weekly. Intervention 2: The con
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age over 18 years A test of the fecal antigen of the Helicobacter pylori or Rapid urease test (RUT) is positive All patients with functional dyspepsia of the pseudo-ulcer type who did not respond to (or recurring) acid reflux therapy, or the presence or history of gastric or duodenal peptic ulcer in a patient or first-degree relatives of patients with gastric cancer Informed consent Form
Exclusion criteria
Exclusion criteria: The history of epilepsy History of chronic diseases (CHB, CKD, COPD, recurrent CVA or dementia, liver cirrhosis) Patients own cancers Severe psychiatric illnesses such as schizophrenia, major depression, bipolar disorders History of antibiotic use in the last 6 weeks Patients with dyspepsia with a predominant symptom of reflux Drug, alcohol and cigarettes History of gastric surgeries, IBD, diabetes, pathological weight loss (weight loss over 10% of body weight over the past 6 months) Anemia (Hemoglobin in men under 14 in males under 11 and in menopausal women under 12 (1)) Diabetes (if FBS is greater than or equal to 126 or HbA1c greater than or equal to 6.5%) corticosteroids use in the last 3 months Use of vitamin D supplements with therapeutic doses during the last 3 months or during the study Participate in another research project over the past 3 months Pregnancy or breastfeeding History of H pylori infection treatment in the past History of kidney stones Participants' unwillingness to take medication or placebo History of any allergy or side effects BMI greater than 40
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| H-pylori Infection. Timepoint: At the beginning of the study before the intervention and 4 months after taking oral vitamin D. Method of measurement: Stool-Antigen test Or RUT. | — |
Secondary
| Measure | Time frame |
|---|---|
| Bloating. Timepoint: At the beginning of the study and after 4 months. Method of measurement: Questionnaire and self-declaration.;Nausea and vomiting. Timepoint: At the beginning of the study and after 4 months. Method of measurement: Questionnaire and self-declaration.;Abdominal pain. Timepoint: At the beginning of the study and after 4 months. Method of measurement: Questionnaire and self-declaration. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAbolfazl Zendehdel
Tehran University of Medical Sciences
Outcome results
None listed